Management of Acute Lithium Restart and Toxicity Monitoring

Immediate Assessment

• Obtain a serum lithium concentration urgently (ideally 12 h after the most recent dose) and evaluate the patient for clinical signs of lithium toxicity, such as neurological (tremor, ataxia, confusion) and gastrointestinal symptoms. 1
• Diarrhea, vomiting, and nausea are recognized gastrointestinal manifestations of lithium toxicity. 2

Baseline Laboratory Evaluation

• Before continuing lithium, order baseline studies that include renal function (BUN, creatinine, estimated clearance), thyroid function (TSH, free T4), a complete blood count, serum calcium (to screen for hyperparathyroidism), and a pregnancy test when appropriate. [3][4][1][5]

Therapeutic‑Level Management (Lithium 0.6–1.2 mmol/L, No Toxicity)

• Continue lithium therapy and adjust the dose to a maintenance range (approximately 550–925 mg daily, individualized by age and weight). [1][5]
• Implement a structured monitoring schedule:
  
  • Lithium serum levels every 3–6 months once stable. 1
  • Renal function (creatinine, BUN) every 3–6 months. 1
  • Thyroid function (TSH, free T4) every 3–6 months. 1
  • Annual urinalysis. 1
• Educate the patient that dose adjustments must be made only under medical supervision and that abrupt changes can precipitate toxicity. 1

Toxicity Management (Lithium > 1.5 mmol/L or Clinical Toxicity)

• Discontinue lithium immediately when toxic levels or clinical toxicity are identified. 1
• For severe toxicity (levels > 2.5 mmol/L or severe symptoms), consider aggressive hydration, electrolyte management, and consultation with nephrology for possible hemodialysis, the most effective method for rapid lithium removal. 1
• If lithium must be stopped, alternative mood stabilizers such as valproate or carbamazepine may be employed. [1][5]

Long‑Term Maintenance Therapy

• Bipolar disorder generally requires maintenance lithium therapy for at least 12–24 months after mood stabilization. [2][6]3
• Relapse rates exceed 80 % after lithium discontinuation, indicating that many patients need lifelong therapy. [6][4]
• Abrupt discontinuation markedly raises relapse risk, particularly within the first 6 months. [6][4]

Safety and Monitoring Principles

• Initiation of lithium should occur only in settings where routine laboratory monitoring is feasible. 1
• The therapeutic window is narrow (therapeutic 0.6–1.2 mmol/L versus toxic > 1.5 mmol/L); vigilant monitoring is essential. 1
• Neurotoxic effects may be delayed and can emerge after serum levels have normalized; continued observation for new neurological symptoms is advised for several days post‑correction. 1